Insulin glargine is cost-effective in treatment of patients with diabetes type-2 in whom nph insulin does not provide adequate glycaemic control – The case of poland

May 1, 2013, 00:00 AM
10.1016/j.jval.2013.03.824
https://www.valueinhealthjournal.com/article/S1098-3015(13)00895-4/fulltext
Section Title : Diabetes/Endocrine Disorders
Section Order : 374
First Page : A165
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)00895-4&doi=10.1016/j.jval.2013.03.824
HEOR Topics :
Tags :
Regions :